Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects
- 13 June 1996
- journal article
- clinical trial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 59 (6) , 636-646
- https://doi.org/10.1016/s0009-9236(96)90003-x
Abstract
Interferon alfa-2a was chemically modified by the covalent attachment of a polyethylene glycol (PEG) moiety to enhance its circulating half-life and to reduce its immunogenicity. A comparative evaluation of the pharmacokinetics of the PEG-modified interferon alfa-2a showed a greater than twofold increase in the circulating half-life as a result of this chemical modification. An indirect physiologic response model was developed to characterize the time course of the MX protein response after subcutaneous administra- tion of single ascending doses of either interferon alfa-2a or PEG-interferon alfa-2a in healthy volunteers. Analysis of the pharmacokinetic-pharmacodynamic relationship suggested that the PEG-modified inter- feron alfa-2a could not be administered less than twice weekly and therefore offered little therapeutic advantage over its unmodified counterpart, which is administered three times weekly. These results were consistent with findings in phase II trials. This study substantiates the usefulness of pharmacodynamic modeling as a tool for the development of dose recommendations and for the early selection of drug candidates in the drug development process. (Clin Pharmacol Ther 1996;59:636-46.)Keywords
This publication has 24 references indexed in Scilit:
- Influence of Human Serum Albumin Content in Formulations on the Bioequivalency of Interferon Alfa‐2a Given by Subcutaneous Injection in Healthy Male VolunteersThe Journal of Clinical Pharmacology, 1995
- Functional Role of Type I and Type II Interferons in Antiviral DefenseScience, 1994
- Comparison of four basic models of indirect pharmacodynamic responsesJournal of Pharmacokinetics and Biopharmaceutics, 1993
- Interferon-?? in Malignant and Viral DiseasesDrugs, 1993
- Double-Blind Randomized Phase I Study on the Clinical Tolerance and Biological Effects of Natural and Recombinant Interferon-βJournal of Interferon Research, 1992
- Antiviral actions of interferon interferon-regulated cellular proteins and their surprisingly selective antiviral activitiesVirology, 1991
- The clinical efficacy of poly(ethylene glycol)-modified proteinsJournal of Controlled Release, 1990
- Time Course of Interferon Levels, Antiviral State, 2′,5′-Oligoadenylate Synthetase and Side Effects in Healthy MenJournal of Interferon Research, 1987
- Treatment of Chronic Non-A, Non-B Hepatitis with Recombinant Human Alpha InterferonNew England Journal of Medicine, 1986
- Virus interference. I. The interferonProceedings of the Royal Society of London. B. Biological Sciences, 1957